Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients

Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients
Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), sponsored by Janssen, is testing 300 mg daily Zejula in patients whose disease worsened after treatment with next-generation androgen-receptor signaling therapies — a mainstay in the treatment of prostate cancer — and the chemotherapy docetaxel. All participants tested positi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *